QUANTIFICATION OF ANTICOAGULANTS DABIGATRAN, RIVAROXABAN, AND PRASUGREL BY CHROMATOGRAPHIC AND SPECTROMETRIC TECHNIQUES – REVIEW

SATYA PRASAD B; JAYAKUMARI S

doi:10.22159/ajpcr.2019.v12i4.29954

Authors

SATYA PRASAD B Department of Pharmacognosy, School of Pharmaceutical Sciences, Vistas, Chennai, Tamil Nadu, India.
JAYAKUMARI S Department of Pharmacognosy, School of Pharmaceutical Sciences, Vistas, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2019.v12i4.29954

Keywords:

Rivaroxaban, Dabigatran, Quantification, Prasugrel, Analyte

Abstract

A review is presented on different analytical techniques used for quantitative analysis of selected anticoagulants dabigatran, rivaroxaban, and prasugrel. Efforts have been made to collate all the relevant references to the extent possible. The review discusses the advantages and disadvantages of the cited analytical techniques, which will help to give insights into the methods used for estimation of selected anticoagulants such as dabigatran, rivaroxaban, and prasugrel, from clinical isolates, and its dosage forms. The review highlights the basic as well as advanced techniques performed for estimating dabigatran, rivaroxaban, and prasugrel. The techniques illustrated here have been demonstrated to be useful for quantitative determination of selected anticoagulants and may find application in analyzing other related properties.

Downloads

Download data is not yet available.

Author Biography

SATYA PRASAD B, Department of Pharmacognosy, School of Pharmaceutical Sciences, Vistas, Chennai, Tamil Nadu, India.

DEPARTMENT OF PHARMACEUTICAL ANALYSIS

References

Tripathi KD. Essentials of Medical Pharmacology. 6th ed. Jaypee Brothers Medical Publishers (P) Ltd.; 2008. p. 597-605.

Jayavarapu KR, Satyanarayana T, Baby B, Kesavarao CH, Sujatha K, Ramya K, et al. Validated UV-spectroscopic method for the estimation of dabigatran etexilate mesylate in formulation and tablet dosage form. Indo Am J Pharm Res 2016;6:4952-6.

Prajapati A, Kumar S, Sen AK, Zanwar A, Seth AK. Spectrophotometric method for estimation of dabigatran etexilate in bulk and its pharmaceutical dosage form. Pharm Sci Monit 2014;5:31-9.

Hepsebah NJ, Kumar AA. Spectrometric dissolution method for dabigatran etexilate mesylate capsules. World J Pharm Pharm Sci 2018;7:1277-90.

Harini U, Madhavilatha N, Pawar AK. Development and validation of UV spectrophotometric method for the estimation of dabigatran etexilate mesylate (dem). Int J Pharm Anal Res 2016;5:218-23.

El-Din MS, Ibrahim F, Shalan SH, El-Aziz HA, Spectrophotometric methods for simultaneous determination of rivaroxaban and clopidogrel in their binary mixture. Pharm Anal Acta 2018;9:1-9.

Seshamamba BS, Sekaran CB, Spectrophotometric quantification of direct factor xa inhibitor, rivaroxaban, in raw and tablet dosage form. Glob Drugs Ther 2017;2:1-8.

Sekaran CB, Bind VH, Damayanthi MR, Sireesha A. Development and validation of UV spectrophotometric method for the determination of rivaroxaban. Der Pharm Chem 2013;5:1-5.

Sreeja U, Gurupadayya BM, Chandan RS, Novel spectrophotometric methods for the quantification of desvenlafaxine in pure and pharmaceutical dosage form. Asian J Pharm Clin Res 2015;8:267-70.

Bagga P, Khan MS, Siddiqui MH, Mahmood T, Siddiqui HH, Colorimetric estimation of prasugrel in bulk and pharmaceutical formulations. Int J Curr Res 2011;3:418-20.

Harshini B, Alekhya SV, Manasa G, Prakash KV, Extractive spectrophotometric estimation of prasugrel in pharmaceutical formulation. Res J Pharm Biol Chem Sci 2011;2:426-30.

Sowndarya P, Mounika K, Prasanna SL, Sandya K, Kumar AA. Assay method development and validation of dabigatrn etexilate in capsules by UV spectroscopy. Int J Pharm Pharm Sci 2015;7:282-5.

Seshamamba BS, Sekaran CB. Spectrophotometric analysis for the quantification of rivaroxaban in bulk and tablet dosage form. Int J Med Pharm Sci 2017;7:21-34.

Alvi SN, Patel MN, Kathiriya PB, Patel BA, Parmar SJ. Simultaneous determination of prasugrel and aspirin by second order and ratio first order derivative ultraviolet spectrophotometry. J Spectrosc 2013;2013:1-7.

Çelebier M, Kaynak MS, Altınöz S, Sahin S. UV Spectrophotometric method for determination of the dissolution profile of rivaroxaban. Dissolution Technol 2014;21:56-9.

Rajendiran RK, Sekar VK, Namadevan BD, Annamalai JK, Devarajan S. UV-spectrophotometric and RP-HPLC methods for the estimation of prasugrel hydrochloride in bulk and tablet formulation. Int J Pharm Pharm Sci 2014;6:220-5.

Mehta AR, Maheshwari DG. Development and validation of first UV spectrophotometric method and RP-HPLC method for simultaneous estimation of rivaroxaban and ticagrelor in synthetic mixture. J Glob Trends Pharm Sci 2018;9:5275-97.

Geetharam Y, Mallesh M, Gupta VR, Sridhar B, Srividya E, Subhash S. Validated stability-indicating liquid chromatographic method for the determination of dabigatran etexilate (thrombin inhibitor) in capsules. Indo Am J Pharm Res 2014;4:2141-50.

Abdallah MA, Al-Ghobashy MA, Lotfy HM. Investigation of the profile and kinetics of degradation of rivaroxaban using HPLC, TLC-densitometry and LC/MS/MS: Application to pre-formulation studies. Bull Fac Pharm Cairo Univ 2015;53:53-61.

Nagadeep J, Kamaraj P, Arthanareeswari M. Gradient RP-HPLC method for the determination of potential impurities in dabigatran etexilate in bulk drug and capsule formulations. Arab J Chem 2015;30:1-13.

Kumar SA, Debnath M, Rao JS, Sankar DG. Validation of developed method by RP-HPLC for estimation of prasugrelin human plasma and studying the stability of the drugs in plasma. Kathmandu Univ J Sci Eng Technol 2017;13:65-75.

Damle MC, Bagwe RA. Development and validation of stability-indicating RP-HPLC method for estimation of dabigatran etexilate. J Adv Sci Res 2014;5:39-44.

Ishaq BM, Prakash KV, Mohan GK. Analytical method development and validation of prasugrel in bulk and its pharmaceutical formulation using the RP-HPLC method. Pharm Methods 2011;2:173-7.

Sagar PV, Samidha MT, Krishna V, Rani SS. A validated RP-HPLC method for simultaneous estimation of aspirin and prasugrel in tablet dosage form. Int J Pharm Sci Res 2014;5:4858-64.

Sahoo S, Mekap SK. Assay comparison of rivaroxaban by new HPLC method with an existing method in tablet dosage form. Pharm Biol Eval 2017;4:180-2.

Manasa P, Sowndarya P, Mounika K, Kumar AA. A rapid stability indicating RP-HPLC assay method development and validation for the quantitative estimation of dabigatran etexilate mesylate in capsules. Indo Am J Pharm Sci 2015;2:1382-92.

Souri E, Mottaghi S, Zargarpoor M, Ahmadkhaniha R, Jalalizadeh H. Development of a stability-indicating HPLC method and a dissolution test for rivaroxaban dosage forms. Acta Chromatogr 2016;28:347-61.

Seshamamba BS, Satyanarayana PV, Sekaran CB. Application of stability indicating HPLC method with UV detector to the analysis of rivaroxaban in bulk and tablet dosage form. Chem Sci Trans 2014;3:1546-54.

Reddy MN, Sekhar KB, Kavitha A, Goud ES. Development and validation of a reverse-phase liquid chromatographic method for related substances of prasugrel for 5 and 10mg tablets. Int J Pharm Pharm Sci 2014;6:90-4.

Nawale R, Pol S, Puranik P, Daud A, Rajkondawar V. Analytical method development and validation of dabigatran etexilate related substance in pharmaceutical dosage form by reverse-phase-high-performance liquid chromatography. Asian J Pharm Clin Res 2018;11:357-64.

Bhavani G, Hussain SS, Ranjith CH, Kumar AA. Dissolution method development and validation of dabigatran etexilate mesylate capsules by RP-HPLC. Am J Pharm Tech Res 2016;6:200-15.

Balaji M, Chhabda PJ, Srinivasarao V, Rao KM, Ramakrishna K. A new and stability indicating liquid chromatographic method for the determination of dabigatran in bulk drug and pharmaceutical dosage form. Anal Chem Au Indian J 2014;14:264-73.

Bernardi RM, Fröehlich PE, Bergold AM. Development and validation of a stability-indicating liquid chromatography method for the determination of dabigatran etexilate in capsules. J AOAC Int 2013;96:37-41.

Patel BA, Alvi S, Parmar SJ. Development and validation of stability indicating HPTLC method for simultaneous estimation of prasugrel and aspirin. EJBPS 2015;2:718-29.

Avachat AM, Yamgar MB. RP-HPLC method development and validation for the estimation of rivaroxaban in bulk and tablet dosage form. World J Pharm Pharm Sci 2017;6:1775-84.

Liu C, Yu Z, Wang F, Zhong X, Jiang L, Zhang F, et al. Isolation and structural elucidation of an unknown impurity in prasugrel by semi-preparative liquid chromatography. J Chromatogr Sci 2015;53:1163-8.

Reddy BR, Rao NV. A stability indicating RP-HPLC method for estimation of dabigatran in pure and pharmaceutical dosage forms. SPJPBS 2014;2:80-92.

Ishaq BM, Prakash KV, Mohan GK. Development and validation of HPLC method for determination of prasugrel in bulk and its pharmaceutical formulation. J Chem Pharm Res 2011;3:404-9.

Parmar SJ, Patel BA, Jain AP. Development and validation of RP-HPLC method for prasugrel. J Chem Pharm Res 2012;4:3373-6.

Hadagali MD. Determination of rivaroxaban in pure, pharmaceutical formulations and human plasma samples by RP-HPLC. Int J Adv Pharm Anal 2015;5:65-8.

Srinivas A, Reddy KS, Sai G. Method development and validation of dabigatran etexilate mesylate by RP-HPLC method and its degradation studies. Int J Trends Pharm Life Sci 2016;2:769-77.

Sonia K, Hamunyare N, Manikandan K. Method development and validation of prasugrel tablets by RP HPLC. J Pharm Sci Res 2017;9:1133-8.

Walter ME, Perobelli RF, Da Silva FS, Júnior CD, Da Silva IS, Dalmora SL. Development and validation of a stability-indicating RP-HPLC method for the determination of rivaroxaban in pharmaceutical formulations. Lat Am J Pharm 2015;34:1503-10.

Prajapati AM, Patel HA. Simultaneous RP-HPLC method development and validation of clopidogrel and rivaroxaban in synthetic mixture. Int J Pharm 2015;5:610-3.

Sriram V, Sriram K, Angirekula J, Tripathi UM, Nayakanti D. Development and validation of reverse phase HPLC method for the determination of impurities in prasugrel hydrochloride. Int J Pharm Tech Res 2012;4:1407-16.

Kasad PA. Photolytic-thermal degradation study and method development of rivaroxaban by RP-HPLC. Int J Pharm Tech Res 2013;5:1254-63.

Raja MA, Vuyyala L, Banji D, Rao KN, Kumar DS. Development of RP-HPLC method and its validation for estimation of prasugrel hydrochloride. Asian J Res Chem Pharm Sci 2015;3:90-4.

Rigobello C, Barden AT, Steppe M. LC method for determination of prasugrel and mass spectrometry detection for thermal and alkaline degradation products. Pharmazie 2015l;70:515-21.

Ahirrao VK, Patil CS, Bembalkar SB, Ubale SB, Marathe RP, Nawale RB, et al. Stability-indicating LC method for the determination of prasugrel hydrochloride in pharmaceutical dosage form. Sci Pharm 2012;80:379-91.

Modi VJ, Pingale PL. Development and validation of analytical method for estimation of prasugrel hydrochloride in bulk and in pharmaceutical formulations. Int J Pharm Bio Sci 2012;3:292-8.

Kumar SA, Rao JV, Rani KJ, Madhuri SS, Prasad TS. Development and validation of RP-HPLC method for the estimation of prasugrel in bulk as well in pharmaceutical dosages form. Int Res J Pharm 2013;4:254 60.

Shivashankar V, Gandhimathi M, Ravi TK. Development of validated RP HPLC method for estimation of rivaroxaban in pharmaceutical formulation. Int J Pharm Anal Res 2015;4:406-10.

Latha NM, Supriya P, Ramana GV, Rohith KB, Chaitanya G, Pawar AK. Development and validation of RP HPLC method for the estimation of dabigatran etexilate mesylate (DEM) in bulk form. Int J Pharm Anal Res 2016;5:141-7.

Dare M, Jain R, Pandey A. Method validation for stability indicating method of related substance in active pharmaceutical ingredients dabigatran etexilate mesylate by reverse phase chromatography. J Chromatogr Sep Tech 2015;6:1-10.

El Zaher AA, El Kady EF, El Houssini OM, El Ghwas HE. Development and validation of stability-indicating rp-lc method for the determination of dabigatran etexilate mesylate in bulk and pharmaceutical formulations. Curr Sci Int 2015;4:402-8.

Patel B, Roy S, Ghelani H, Parmar S. Development and validation of RP-HPLC method for estimation of dabigatran etexilate mesylate from capsule dosage form. Int J Pharm Sci Res 2017;8:143-51.

Çelebier M, Reçber T, Koçak E, Altınöz S. RP-HPLC method development and validation for estimation of rivaroxaban in pharmaceutical dosage forms. Braz J Pharm Sci 2013;49:359-66.

Girase YN, Soni SV. Development and validation of stability indicating RP-HPLC method for rivaroxaban and its impurities. SOJ Biochem 2018;4:1-6.

Rajan N, Basha KA. A stability-indicating ultra-performance liquid chromatographic method for estimation of related substances and degradants in rivaroxaban active pharmaceutical ingredient. J Pharm Res 2014;8:1719-25.

El-Aziz HA, Ibrahim F, El-Din MS, Fathy ME. Micellar high performance liquid chromatographic determination of a binary mixture of rivaroxaban and clopidogrel and application to biological fluids. Pharm Anal Acta 2016;7:1-11.

Meenakshi R, Rao RN. RP-HPLC method development and validation for determination of rivaroxaban in the pure and pharmacuetical dosage form. J Chem Pharm Res 2016;8:38-44.

Sahani S, Jain V. A novel reversed-phase high-performance liquid chromatography method for simultaneous estimation of drotaverine hydrochloride, ethamsylate, and tranexamic acid in tablet dosage form. Asian J Pharm Clin Res 2018;11:121-5.

Sunny A, Sreedhar C, Rao TS, Akkama HG, Mahapatra A. Development of new analytical method and validation for quantitative estimation of rivaroxaban in formulation and bulk drug. Int J Sci Res Educ 2017;5:6469-78.

Prajapati PB, Rakholiya AJ, Bodiwala KB, Marolia BP, Shah SA. Stability indicating HPTLC method for estimation of dabigatran etexilate mesylate in its pharmaceutical dosage form. Eurasian J Anal Chem 2017;12:75-86.

Vaghela D, Patel P. High performance thin layer chromatographic method with densitometry analysis for determination of rivaroxaban from its tablet dosage form Int J Pharm Pharm Sci 2014;6:383-6.

Srikanth I, Sharmila P, Vijayabharathi K, Raju M, Naik ML, Nagarjuna K. A validated reverse phase HPLC method for the estimation of prasugrel hydrochloride in pharmaceutical dosage forms. J Indones Tour Policy Sci 2011;2:140-8.

Ruzilawati AB, Miran H. Validated high performance liquid chromatography method for analysis of methamphetamine in human urine using liquid-liquid extraction. Asian J Pharm Clin Res 2015;8:199 201.

Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg EM, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013;1:1-7.

Srikanth I, Rani AP. Development and validation of liquid chromatography coupled with tandem mass spectrometry method for estimation of lenvatinib in human plasma. Asian J Pharm Clin Res 2017;10:120-6.

Schmitz EM, Boonen K, Den Heuvel DJ, Van Dongen JL, Schellings MW, Emmen JM, et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014;12:1636-46.

Zhang WL, Lou D, Zhang DT, Zhang Y, Huang HJ. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. J Thromb Thrombolysis 2016;42:205-11.

Reddy GS, Reddy SL, Reddy LS. Development and Validation of HPLC-MS/MS method for rivaroxaban quantitation in human plasma using solid phase extraction procedure. Orient J Chem 2016;32:1145 54.

Derogis PB, Sanches LR, de Aranda VF, Colombini MP, Mangueira CL, Katz M, et al. Determination of rivaroxaban in patient’s plasma samples by anti-xa chromogenic test associated to high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). PLoS One 2017;12:e0171272.

Puram SR, Batheja R, Nithya G. Highly sensitive and rapid evaluation of pyridostigmine impurity b in human plasma by liquid chromatography coupled with tandem mass spectrometer after administration of pyridostigmine to healthy volunteers in a pharmacokinetic study. Asian J Pharm Clin Res 2018;11:353-7.

Yadav S, Dubey N. Development and validation of bioanalytical method for estimation of rivaroxaban using HPLC-PDA in human blood plasma. J Drug Deliv Ther 2017;7:123-5.